Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Genetics Generation Advancement Net Margin %?
Genetics Generation AdvancementROCO:4160 -1.20%70 Net Margin % is 6.56% as of Dec. 2025, which is 68% above its 10-year median of 3.90. GuruFocus rates ROCO:4160 with a GF Score™ of 70/100 and a GF Value™ of NT$51.35 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Genetics Generation Advancement ranks better than 61.76% on this metric.
The historical rank and industry rank for Genetics Generation Advancement's Net Margin % or its related term are showing as below:
ROCO:4160'
s Net Margin % Range Over the Past 10 Years
Min: -3.54 Med: 3.9 Max: 8.26
Current: 3.54
ROCO:4160's Net Margin % is ranked better than 61.76% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.75
vs ROCO:4160: 3.54
Genetics Generation Advancement (ROCO:4160) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Genetics Generation Advancement Net Margin % Related Terms
Genetics Generation Advancement Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genetics Generation Advancement Net Margin % Chart
ROCO:4160 vs TMO, DHR, IDXX: Net Margin % Comparison
For the Diagnostics & Research subindustry, Genetics Generation Advancement's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genetics Generation Advancement Net Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Genetics Generation Advancement's Net Margin % distribution charts can be found below:
* The bar in red indicates where Genetics Generation Advancement's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genetics Generation Advancement (ROCO:4160) has a Net Margin % of 6.56% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Genetics Generation Advancement and its competitors. This is 68% above median its historical median of 3.90. According to the industry distribution chart, Genetics Generation Advancement ranks #78 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 38.2%.
Is Genetics Generation Advancement's Net Margin % too high?
Genetics Generation Advancement's current Net Margin % of 6.56% is 68% above median its 10-year median of 3.90. Based on the distribution chart, Genetics Generation Advancement ranks #78 out of 204 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Genetics Generation Advancement has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genetics Generation Advancement's Net Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Genetics Generation Advancement ranks #78 out of 204 companies for Net Margin %. This puts Genetics Generation Advancement in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Diagnostics & Research company?
A good Net Margin % depends on the Medical Diagnostics & Research industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Genetics Generation Advancement and its competitors. Genetics Generation Advancement's current Net Margin % is 6.56%, which is 68% above median its own 10-year median of 3.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetics Generation Advancement stock overvalued right now?
Based on GuruFocus' analysis, Genetics Generation Advancement (ROCO:4160) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$51.35, compared to a current price of NT$41.15 — trading 19.9% below its estimated fair value. The current Net Margin % is 6.56%, which is 68% above median its 10-year median of 3.90. Genetics Generation Advancement's overall GF Score™ is 70/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Genetics Generation Advancement (ROCO:4160), the current Net Margin % is 6.56% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genetics Generation Advancement (ROCO:4160) Overvalued in 2026?
Based on GuruFocus' analysis, Genetics Generation Advancement stock appears to be undervalued.
The current stock price of NT$41.15 is trading 19.9% below its estimated GF Value™ of NT$51.35.
GuruFocus considers Genetics Generation Advancement to be Modestly Undervalued.
Key valuation signals for ROCO:4160:
Net Margin %: 6.56% (68% above median its 10-year median of 3.90)
GF Value™: NT$51.35 vs. price of NT$41.15 (19.9% below fair value)
No single metric tells the full story. See the ROCO:4160 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genetics Generation Advancement Business Description
Genetics Generation Advancement Corp is a Taiwan based company specialized in genetic testing and scientific information. It is engaged in providing services for the detection of genetic defects and prevention in newborns. Their main services include amniotic fluid chromosome chip screening, pre-implantation genetic diagnosis, and Molecular DNA testing diagnostics. The company is focused on the majority of areas of maternal precision medicine, pediatric disease diagnosis, drug-associated diagnosis, non-invasive cancer detection, and precise health management. The business units of the company are the Genetic Testing Unit and Informatics business unit.
70GF Score
Get the complete analysis for ROCO:4160
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4160 has been successfully added to your 
